NAS-AMP

全球卫生保健系统的抗菌素耐药性相关成本估计每年超过100亿欧元。如果不解决抗生素耐药性问题，经济影响预计将呈指数级上升。在医院，特别是重症监护病房（ICU）环境中，MRSA感染对患者的健康、传播给其他患者的风险以及管理和消除感染的成本非常严重。本项目的目的是开发一种用抗菌肽（AMP）进行鼻腔治疗以根除MRSA携带。Madam Therapeutics（Madam）和莱顿大学医学中心（LUMC）先前开发的合成AMP已被证明对耐药性细菌菌株完全有效。北方爱尔兰的SiSaf有限公司将与Madam和LUMC合作，利用其专利技术平台为该项目中的活性AMP进行专业的纳米颗粒药物配制，并将与利物浦大学合作，在匈牙利进行微生物学研究和ToxiCoop药理学服务。该项目的标题是“开发一种含有抗菌肽的新型鼻腔疗法来治疗MRSA携带”，该项目由欧盟EUROSTARS计划资助，用于学术和工业研究合作。欧洲之星是研究尤里卡和欧洲联盟委员会之间的一个联合方案，由34个欧洲之星参与国和伙伴国的国家预算以及欧洲联盟通过“地平线2020”共同供资。英国合作伙伴的资金来自Innovate UK。

The antimicrobial resistance-related costs to the global health care system are estimated at >10 billion Euro peryear. The economic impact is expected to exponentially rise if antimicrobial resistance is not tackled. Infections with MRSA in hospitals, and in particularly Intensive Care Units (ICU) settings, are very serious in terms of the patient’s health, risk of spreading to other patients and the costs of managing and eliminating the infection. The aim of this project is to develop a nasal therapy with antimicrobial peptides (AMPs) to eradicate MRSA carriage. The synthetic AMPs that were previously developed by Madam Therapeutics (Madam) and Leiden University Medical Center (LUMC) have shown to be fully effective against antibiotic-resistant bacterial strains. In collaboration with Madam and LUMC, SiSaf Ltd in Northern Ireland will undertake specialist nanoparticle drug formulation with its patented technology platform for the active AMPs in the project and will include collaboration with the University of Liverpool in relation to microbiology studies and ToxiCoop Pharmacology services in Hungary. The project title is “Development of a novel nasal therapy containing antimicrobial peptides to treat MRSA carriage” and it is funded under the EU EUROSTARS programme for academic and industrial research collaboration. EUROSTARS is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 34 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020. The UK partner funding is through Innovate UK.